First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial; Niels W. C. J. van de Donk; Rakesh Popat; Jeffrey A. Zonder; Monique C. Minnema; Jeremy Larsen; Tuong Vi Nguyen; Min S. Chen; Amine Bensmaine; Mariana Cota; Pieter Sonneveld

First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, Niels W. C. J. van de Donk, Rakesh Popat, Jeffrey A. Zonder, Monique C. Minnema, Jeremy Larsen, Tuong Vi Nguyen, Min S. Chen, Amine Bensmaine, Mariana Cota, Pieter Sonneveld

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Journal	Journal of Clinical Oncology
Volume	37
Issue number	15
Publication status	Published - 20 May 2019

Cite this

Lonial, S., van de Donk, N. W. C. J., Popat, R., Zonder, J. A., Minnema, M. C., Larsen, J., Tuong Vi Nguyen, Chen, M. S., Bensmaine, A., Cota, M., & Sonneveld, P. (2019). First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Journal of Clinical Oncology, 37(15).

@article{6e1ac36a3cf44bf6871113e63eee7a80,

title = "First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).",

author = "Sagar Lonial and {van de Donk}, {Niels W. C. J.} and Rakesh Popat and Zonder, {Jeffrey A.} and Minnema, {Monique C.} and Jeremy Larsen and {Tuong Vi Nguyen} and Chen, {Min S.} and Amine Bensmaine and Mariana Cota and Pieter Sonneveld",

year = "2019",

month = may,

day = "20",

language = "English",

volume = "37",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "15",

}

Lonial, S, van de Donk, NWCJ, Popat, R, Zonder, JA, Minnema, MC, Larsen, J, Tuong Vi Nguyen, Chen, MS, Bensmaine, A, Cota, M & Sonneveld, P 2019, 'First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).', Journal of Clinical Oncology, vol. 37, no. 15.

First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). / Lonial, Sagar; van de Donk, Niels W. C. J.; Popat, Rakesh et al.
In: Journal of Clinical Oncology, Vol. 37, No. 15, 20.05.2019.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

AU - Lonial, Sagar

AU - van de Donk, Niels W. C. J.

AU - Popat, Rakesh

AU - Zonder, Jeffrey A.

AU - Minnema, Monique C.

AU - Larsen, Jeremy

AU - Tuong Vi Nguyen,

AU - Chen, Min S.

AU - Bensmaine, Amine

AU - Cota, Mariana

AU - Sonneveld, Pieter

PY - 2019/5/20

Y1 - 2019/5/20

M3 - Meeting Abstract

SN - 0732-183X

VL - 37

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

ER -